There are several aspects of human brain tumor gene therapy, which are poorly understood in part due to? the lack of efficient tools to visualize biological processes in vivo. For example, it is difficult to image immune? response during viral oncolysis (Project 1) and to determine the long-term fate of genetically engineered Tcell? or progenitor cells (Project 3). The overall goal of this Project is to develop and optimize in vivo imaging? techniques that can ultimately be used to objectively monitor vector and cell based glioma therapies. The? maging strategies utilized in this Project are based on previously developed agents (e.g. targeted CLIO,? activatable NIRF) adapted to high throughput screening for rapid development. In the first aims, we will? develop injectable cell-specific imaging agents to image native immune cells (CD4, CDS, NK, macrophages)? in their micro-environments using phage and library screens. In parallel we will develop high-efficiency multilabel? cell trackers to follow ex vivo labeled cells by different imaging modalities simultaneously. In the second? aim we shall develop and validate novel imaging agents that are predictive of the efficacy of oncolytic antiglioma? therapies, in particular targets (e.g. aminopeptidase N) that will emerge through rigorous screens.? The goal of the third aim is to develop and validate novel constructs to not only follow neural progenitor cells? in vivo but image their differentiation into terminal cells as a function of time, delivery routes, and microenvironments.? Data from these studies should be highly useful to rapidly evaluate the therapeutic efficacy of? cell-based therapies and to develop more efficient approaches. There is a high degree of interaction with? other Projects and Cores.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA069246-11
Application #
7552783
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2007-03-01
Budget End
2008-02-29
Support Year
11
Fiscal Year
2007
Total Cost
$265,650
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Shao, Huilin; Im, Hyungsoon; Castro, Cesar M et al. (2018) New Technologies for Analysis of Extracellular Vesicles. Chem Rev 118:1917-1950
Ricklefs, Franz L; Alayo, Quazim; Krenzlin, Harald et al. (2018) Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. Sci Adv 4:eaar2766
Park, Jongmin; Im, Hyungsoon; Hong, Seonki et al. (2018) Analyses of Intravesicular Exosomal Proteins Using a Nano-Plasmonic System. ACS Photonics 5:487-494
Antoury, Layal; Hu, Ningyan; Balaj, Leonora et al. (2018) Analysis of extracellular mRNA in human urine reveals splice variant biomarkers of muscular dystrophies. Nat Commun 9:3906
Zhou, Shuang; Appleman, Vicky A; Rose, Christopher M et al. (2018) Chronic platelet-derived growth factor receptor signaling exerts control over initiation of protein translation in glioma. Life Sci Alliance 1:e201800029
Min, Jouha; Nothing, Maria; Coble, Ben et al. (2018) Integrated Biosensor for Rapid and Point-of-Care Sepsis Diagnosis. ACS Nano 12:3378-3384
Lee, Kyungheon; Fraser, Kyle; Ghaddar, Bassel et al. (2018) Multiplexed Profiling of Single Extracellular Vesicles. ACS Nano 12:494-503
ReƔtegui, Eduardo; van der Vos, Kristan E; Lai, Charles P et al. (2018) Engineered nanointerfaces for microfluidic isolation and molecular profiling of tumor-specific extracellular vesicles. Nat Commun 9:175
Speranza, Maria-Carmela; Passaro, Carmela; Ricklefs, Franz et al. (2018) Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma. Neuro Oncol 20:225-235
Boussiotis, Vassiliki A; Charest, Alain (2018) Immunotherapies for malignant glioma. Oncogene 37:1121-1141

Showing the most recent 10 out of 223 publications